Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene
| Autor: | Francesco Orio, Annamaria Colao, Annalidia Sammartino, Pasquale Mastrantonio, Stefano Palomba, Gaetano Lombardi, Fulvio Zullo, Carmine Nappi, Francesco Maria Sbano, Tiziana Russo |
|---|---|
| Přispěvatelé: | Palomba, Stefano, Russo, T., Orio, Francesco, Sammartino, A., Sbano, F. M., Nappi, Carmine, Colao, Annamaria, Mastrantonio, P., Lombardi, Gaetano, Zullo, F. |
| Rok vydání: | 2004 |
| Předmět: |
Blood Glucose
Homocysteine medicine.medical_treatment Body Mass Index raloxifene Placebos chemistry.chemical_compound Homeostasis Insulin glucose GnRH agonist Leiomyoma Rehabilitation leiomyomas Obstetrics and Gynecology Middle Aged Lipid Lipids Vitamin B 12 Cholesterol Uterine Neoplasms Female metabolism selective estrogen receptor modulators medicine.drug Adult medicine.medical_specialty Folic Acid Insulin resistance Internal medicine medicine Humans Raloxifene Triglycerides Raloxifene Hydrochloride business.industry Cholesterol HDL Cholesterol LDL homocysteine medicine.disease Endocrinology Premenopause Reproductive Medicine Blood chemistry chemistry Delayed-Action Preparations Body Constitution Insulin Resistance Leuprolide business Lipoprotein |
| Zdroj: | Human Reproduction. 19:415-421 |
| ISSN: | 1460-2350 |
| DOI: | 10.1093/humrep/deh053 |
| Popis: | BACKGROUND: Although GnRH analogues are widely used to treat a variety of sex hormone-related diseases, little is known about their effect on metabolism. Therefore, we have evaluated the effect of a GnRH analogue, administered with or without raloxifene, on serum levels of lipoproteins, glucose, insulin and homocysteine (Hcy). METHODS: One hundred premenopausal women with symptomatic uterine leiomyomas were initially enrolled and randomized to receive 3.75 mg/28 days leuprolide acetate depot associated with 60 mg/day raloxifene hydrochloride (group A) or 1 placebo tablet/day (group B) for six cycles of 28 days. At entry and at cycle 6, subjects underwent anthropometric measurements, including body mass index and waist-to-hip ratio measurements, and blood chemistry assays for serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), glucose, insulin, Hcy, vitamin B(12) and folate concentrations. Insulin resistance was evaluated with the homeostasis model assessment (HOMA) score. RESULTS: Baseline parameters were similar in the two groups. At cycle 6, TC, HDL-C, LDL-C and TG levels were significantly increased (P < 0.05) in group B. In group A, LDL-C levels were unchanged, and TC, HDL-C and TG levels were increased (P < 0.05). Serum TC and LDL-C levels differed (P < 0.05) between the groups. Glucose levels were unchanged between and within groups, whereas insulin levels and HOMA scores increased (P < 0.05) versus baseline in group B. Post-treatment Hcy levels were higher (P < 0.05) versus baseline in group B; they were unchanged in group A. Serum vitamin B(12) and folate concentrations were unchanged in both groups. CONCLUSIONS: GnRH analogues alter serum lipoprotein and Hcy levels and increase insulin resistance. These acute metabolic changes may be prevented or reduced by raloxifene. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|